中天运会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：标准的无保留意见。 本报告期会计师事务所变更情况：公司本年度会计师事务所由变更为中天运会计师事务所（特殊普通合 伙）。 非标准审计意见提示 证券代码：301393 证券简称：昊帆生物 公告编号：2025-011 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 □适用 √不适用 公司上市时未盈利且目前未实现盈利 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 公司经本次董事会审议通过的利润分配预案为：以实施权益分派股权登记日登记的公司股份总数扣减公 司回购专用证券账户中的股份为基数，向全体股东每10股派发现金红利2.65元（含税），送红股0股 （含税），以资本公积金向全体股东每10股转增0股。 董事会决议通过的本报告期优先股利润分配预案 □适用 □不适用 二、公司基本情况 1、公司简介 ■ 2、报告期主要业务或产品简介 （一）主要业务 公司专注于多肽合成试剂的研 ...

Core Insights - The global animal vaccine market is projected to exceed $14 billion in 2024, following a market size of over $13.5 billion in 2023, with a compound annual growth rate (CAGR) of 10.10% over the past five years [1][8]. Market Overview - Animal vaccines, also known as veterinary vaccines, are products made from pathogenic microorganisms that stimulate the immune system of animals to produce specific antibodies, thereby preventing infectious diseases [1]. - North America, including the United States and Canada, is the largest regional market for animal vaccines, accounting for approximately 45% of the global market share in 2023 [3]. Industry Competition - Leading companies in the global animal vaccine industry offer a diverse range of products, including vaccines for pets, pigs, poultry, ruminants, and aquaculture [5]. - Major players such as Merck Animal Health, Zoetis, and Boehringer Ingelheim have established multiple production bases worldwide, indicating significant production capacity [5]. Company Profiles - **Merck Animal Health**: Offers pet vaccines, pig vaccines, poultry vaccines, and aquaculture vaccines, with 29 production bases across 12 countries, including a major facility in Suzhou, China [6]. - **Zoetis**: Operates production bases in the United States and China, having established its first R&D and production base in China in 2019 [6]. - **Boehringer Ingelheim**: Maintains over 20 production bases globally, with two facilities located in Nanchang and Taizhou, China [6]. - **Hualan Biological Engineering**: Initially focused on blood products, it has become a major producer of influenza vaccines in China, accounting for over 40% of the national market [6]. - **Fubao Animal Health**: Produces vaccines for pigs, poultry, and aquaculture, with production bases in the United States and Suzhou, China [6].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688739 证券简称：成大生物 公告编号：2025-017 辽宁成大生物股份有限公司 关于韶关市高腾企业管理有限公司要约收购结果 暨股票复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 证券停复牌情况：适用 因韶关市高腾企业管理有限公司（以下简称"韶关高腾"）要约收购辽宁成大生物股份有限公司（"公 司"或"成大生物"）股份事项,本公司的相关证券停复牌情况如下： ■ 数为6,939股，约占公司总股本的0.0017%。 ● 本次要约收购期限内，预受要约的股东账户总数为19户，预受要约股份总 ● 本次要约收购完成后，韶关高腾直接持有成大生物股份6,939股，约占公司总股本的0.0017%，公司股 权分布仍符合上市条件，上市地位不受影响。 公司于2025年3月3日披露了《辽宁成大生物股份有限公司要约收购报告书》，韶关高腾向成大生物除辽 宁成大股份有限公司（以下简称"辽宁成大"）之外的其他所有股东，发出收购其持有的无限售条件流通 股的全面要约，本 ...

Group 1: Company Announcements - WuXi AppTec announced the sale of 50.8 million shares of WuXi AppTec Holdings through block trading, with a transaction amount of approximately HKD 2.178 billion, resulting in an investment gain of about RMB 1.847 billion, which accounts for over 10% of the company's latest audited net profit attributable to shareholders [1] - Jinlongyu plans to invest RMB 1.2 billion to construct a production line for key materials for solid-state batteries in Huizhou New Materials Industrial Park [2] - Dazhu CNC is conducting preliminary research on the issuance of overseas securities (H shares) and listing [3] - Anyuan Coal Industry plans to acquire 57% of Jinhui Magnetic Separation and simultaneously divest its coal business, which is expected to constitute a major asset restructuring [4] - Yuntian Lifa announced that its subsidiary has completed the delivery and acceptance of AI training and inference computing power services, positively impacting the company's operational performance [5] - AVIC Industry plans to voluntarily withdraw its A-share listing and will be suspended from trading starting April 3, 2025 [6] Group 2: Financial Performance - Naipu Mining reported a 45.46% year-on-year increase in net profit for 2024 and plans to distribute a cash dividend of RMB 0.7 per 10 shares [7] - New Hope expects a profit of RMB 430 million to RMB 500 million in the first quarter, marking a turnaround from losses [7] - Jinbei Automobile reported a net profit of RMB 382 million for 2024, a year-on-year increase of 214.06% [7] - Hailu Heavy Industry anticipates a year-on-year net profit increase of 50% to 65% for the first quarter of 2025 [8] Group 3: Major Transactions and Investments - Baiyin Nonferrous Metals completed the acquisition of a mining company's equity, increasing its copper metal resources to approximately 930,000 tons [9] - Ningbo Port expects to complete a container throughput of 12.11 million TEUs in the first quarter, a year-on-year increase of 10.9% [11] - Huafeng Communication reported a year-on-year net profit increase of 38.38% for 2024 [11] - Kid King anticipates a year-on-year net profit increase of 72.44% for 2024 and plans to distribute a cash dividend of RMB 0.5 per 10 shares [11]

证券代码：600201 证券简称：生物股份 公告编号：临 2025-011 金宇生物技术股份有限公司 关于股东股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、公司股份解除质押情况 生物控股原质押给中信建投证券股份有限公司的本公司 27,330,000 股无限 售流通股股票已于 2025 年 4 月 1 日解除质押，并已办理完成上述股票解除质押的 相关手续。具体情况如下： | 股东名称 | 内蒙古金宇生物控股有限公司 | | --- | --- | | 本次解质（解冻）股份 | 27,330,000 股 | | 占其所持股份比例 | 22.35% | | 占公司总股本比例 | 2.44% | | 解质（解冻）时间 | 2025 年 4 月 1 日 | | 持股数量 | 122,304,000 股 | | 持股比例 | 10.92% | | 剩余被质押（被冻结）股份数量 | 18,600,000 股 | | --- | --- | | 剩余被质押（被冻结）股份数量占其所 | 15.21% | ...

金宇生物技术股份有限公司 关于子公司取得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600201 证券简称：生物股份 公告编号：临 2025-012 用法与用量：颈部或臀部肌肉注射。充分摇匀，1 月龄以上（含 1 月龄）牛 首免，每头牛 2.0ml。 规格：10ml/瓶、20ml/瓶、50ml/瓶、100ml/瓶 贮藏与有效期:2～8℃保存，有效期为 24 个月。 根据国家《兽药管理条例》和《兽药注册办法》规定，经国家农业农村部审 查，批准金宇生物技术股份有限公司（以下简称"公司"）全资子公司金宇保灵 生物药品有限公司（以下简称"金宇保灵"）和控股子公司辽宁益康生物股份有 限公司（以下简称"辽宁益康"）联合研制的牛产气荚膜梭菌病（A 型）灭活疫苗 （CNM0708 株）为新兽药，详情如下： 一、新兽药产品基本情况 新兽药名称：牛产气荚膜梭菌病（A 型）灭活疫苗（CNM0708 株） 注册分类：二类 新兽药注册证书号：(2025)新兽药证字24号 研制单位：金宇保灵生物药品有限公司、辽宁益康生 ...

| 北京市通商律师事务所 | | | | | --- | --- | --- | --- | | 关于 | | | | | 瑞普生物股份有限公司 | | | | | 2022 回购注销 | | 年限制性股票激励计划部分限制性股 | | | 票相关事项的 | | | | | 法律意见书 | | | | | 二○二五年四月 | | | | | 释 | | 义 | | | 在本《法律意见书》中，除非文义另有所指，下列词语具有下述涵义： | | | | | 瑞普生物、本公司、公司 | 指 瑞普生物股份有限公司 | | | | 《公司章程》 指 | 《瑞普生物股份有限公司章程》 | | | | 《限制性股票激励计划 | 瑞普生物《2022 年限制性股票激励计划（草案）》及 | | | | 指 | | | | | （草案）》 | 其修订稿 | | | | | 公司根据本激励计划规定的条件和价格，授予激励对 | | | | | 象一定数量的公司股票，该等股票设置一定期限的限 | | | | 标的股票/限制性股票 | | | | | | 售期，在达到本激励计划规定的解除限售条件后，方 | | | | | 按照本激励计划规定， ...

瑞普生物股份有限公司 内部控制审计报告 信会师报字2025第 ZG10865 号 内部控制审计报告 信会师报字2025第 ZG10865 号 瑞普生物股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了瑞普生物股份有限公司（以下简称瑞普生物）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 我们认为，瑞普生物于 2024 年 12 月 31 日按照《企业内部控制 基本规范》和相关规定在所有重大方面保持了有效的财务报告内部控 制。 （此页无正文） 立信会计师事务所 中国注册会计师：王娜 （特殊普通合伙） 按照《企业内部控制基本规范》《企业内部控制应用指引》 《企业 内部控制评价指引》的规定，建立健全和有效实施内部控制，并评价 其有效性是瑞普生物董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控 ...

Core Viewpoint - The internal control evaluation report of Reap Bio Co., Ltd. indicates that there are no significant defects in both financial and non-financial reporting internal controls as of the evaluation date, affirming the effectiveness of the company's internal control system [2][14]. Internal Control Objectives - The objectives of the internal control system include ensuring legal compliance in management, safeguarding assets, ensuring the accuracy of financial reporting, improving operational efficiency, and supporting the achievement of strategic goals [2]. Internal Control Evaluation Conclusion - The board of directors confirms that there are no significant defects in financial reporting internal controls and non-financial reporting internal controls as of the evaluation date [2][14]. Internal Control Evaluation Scope - The evaluation covers the company and its wholly-owned and controlled subsidiaries, which account for 100% of total assets and total revenue in the consolidated financial statements [3]. High-Risk Areas - Key high-risk areas evaluated include procurement, sales, engineering activities, fundraising management, human resources, financial activities, asset management, financial reporting, contract management, and information disclosure [3][4]. Procurement Management - The company has established a dedicated supplier development department to manage procurement, adhering to veterinary drug production quality management standards and implementing a comprehensive procurement management system [4]. Sales Management - A complete sales system and process have been established, including credit risk management and a closed-loop management system for sales-related activities to ensure financial safety and improve capital turnover efficiency [5]. Engineering Management - The company has developed an integrated engineering management system that outlines project approval processes, responsibilities, and construction management to enhance project oversight [6]. Fundraising Management - The company has detailed regulations for the management of raised funds, ensuring proper storage, usage, and disclosure, with funds managed in designated accounts [6]. Human Resources Management - The company emphasizes sustainable development in human resources, focusing on ethical standards and professional capabilities in employee selection and training [7]. Financial Activities Management - The company has revised its fund management system to ensure strict control over monetary funds, with clear approval processes and budget management [8]. Asset Management - The company follows a physical asset management system, assigning responsibility for asset management and conducting regular checks to ensure asset safety [9]. Financial Reporting Management - The finance department prepares financial reports in accordance with relevant laws and regulations, ensuring accurate and timely reporting [9]. Contract Management - The company has established a legal review department to oversee contract management processes, ensuring compliance and risk mitigation [10]. Information Disclosure Management - The company has developed internal control systems for information disclosure to ensure the accuracy and completeness of disclosed information, enhancing communication with investors [11].

证券代码：600201 证券简称：生物股份 公告编号：临2025-010 金宇生物技术股份有限公司 关于回购股份比例达到1%暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 回购方案首次披露日 2024/10/31 回购方案实施期限 董事会审议通过后 12 个月 预计回购金额 8,000 万元~16,000 万元 □减少注册资本 √用于员工持股计划或股权激励 回购用途 □用于转换公司可转债 □为维护公司价值及股东权益 累计已回购股数 1,458 万股 累计已回购股数占总股本比例 1.3014% 累计已回购金额 9,985.44 万元 实际回购价格区间 6.37 元/股~7.28 元/股 金宇生物技术股份有限公司（以下简称"公司"）于 2024 年 10 月 30 日召开第 十一届董事会第十七次会议，会议审议并通过《关于以集中竞价交易方式回购公司 股份的议案》，同意公司使用自有资金以集中竞价交易方式回购公司股份用于实施 员工持股计划或股权激励，回购价格不超过人民币 10.01 元/股（含），回购资金总 额不低于人民 ...